External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
View abstract on PubMed
Summary
This summary is machine-generated.The International Metastatic Renal-Cell Carcinoma Database Consortium model accurately predicts survival for patients with metastatic renal-cell carcinoma. This validated model can now be used in clinical trials and for patient counseling.
Area Of Science
- Oncology
- Clinical Epidemiology
- Biostatistics
Background
- The International Metastatic Renal-Cell Carcinoma Database Consortium (IMRCCC) model provides prognostic information for metastatic renal-cell carcinoma (mRCC) patients.
- External validation of the IMRCCC model against other prognostic tools is crucial for its clinical utility.
Purpose Of The Study
- To externally validate the IMRCCC model in an independent cohort of mRCC patients.
- To compare the predictive accuracy of the IMRCCC model with other established prognostic models for mRCC.
Main Methods
- A cohort of 1028 mRCC patients treated with first-line VEGF-targeted therapy across 13 international cancer centers was analyzed.
- The IMRCCC model's performance was assessed using concordance indices and compared against the Cleveland Clinic Foundation (CCF), International Kidney Cancer Working Group (IKCWG), French, and Memorial Sloan-Kettering Cancer Center (MSKCC) models.
- Overall survival was the primary endpoint, with risk factors including anemia, thrombocytosis, neutrophilia, hypercalcemia, Karnofsky performance status <80%, and time from diagnosis to treatment.
Main Results
- The IMRCCC model demonstrated strong predictive accuracy in the external validation set, with a concordance index of 0.71 (95% CI 0.68-0.73).
- Predefined risk factors within the IMRCCC model were independent predictors of poor overall survival (hazard ratios 1.27-2.08).
- Patients stratified into favorable, intermediate, and poor risk groups by the IMRCCC model showed significantly different median overall survival (43.2, 22.5, and 7.8 months, respectively; p<0.0001). The IMRCCC model showed better prediction of deaths at 2 years compared to other models.
Conclusions
- The IMRCCC model is externally validated and reliable for prognostic assessment in mRCC.
- The validated IMRCCC model can be effectively utilized for patient risk stratification in clinical trials.
- The model aids in providing accurate prognostic counseling to patients diagnosed with metastatic renal-cell carcinoma.